Daiichi Sankyo Company 향후 성장

Future 기준 점검 4/6

Daiichi Sankyo Company (는) 각각 연간 14.9% 및 10% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 15.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 20.4% 로 예상됩니다.

핵심 정보

14.9%

이익 성장률

15.30%

EPS 성장률

Pharmaceuticals 이익 성장	10.9%
매출 성장률	10.0%
향후 자기자본이익률	20.43%
애널리스트 커버리지	Good
마지막 업데이트	03 Dec 2025

최근 향후 성장 업데이트

Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year

Nov 04

Earnings Beat: Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 03

Daiichi Sankyo Company, Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Apr 30

Daiichi Sankyo Company, Limited Just Recorded A 8.3% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 04

Recent updates

Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year

Nov 04

Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's

Sep 21

Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's

Sep 05

Daiichi Sankyo Company (TSE:4568) Has Announced That It Will Be Increasing Its Dividend To ¥39.00

Aug 22

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

Aug 07

Earnings Beat: Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 03

Daiichi Sankyo Company (TSE:4568) Is Increasing Its Dividend To ¥39.00

Jul 24

Daiichi Sankyo Company (TSE:4568) Is Increasing Its Dividend To ¥39.00

Jul 09

We Think That There Are Issues Underlying Daiichi Sankyo Company's (TSE:4568) Earnings

Jun 27

Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark

Jun 18

Daiichi Sankyo Company, Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Apr 30

Is Daiichi Sankyo Company (TSE:4568) Using Too Much Debt?

Apr 06

Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark

Feb 26

Daiichi Sankyo Company, Limited Just Recorded A 8.3% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 04

Daiichi Sankyo Company, Limited's (TSE:4568) Intrinsic Value Is Potentially 93% Above Its Share Price

Jan 14

Antibody-Drug Innovation And Strategic Partnerships Pave The Way For Significant Growth

Nov 07 Strategic R&D investments in antibody-drug conjugates and collaborations indicate potential future revenue growth and enhanced market share in oncology.

이익 및 매출 성장 예측

TSE:4568 - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
3/31/2028	2,634,792	445,253	356,421	465,561	15
3/31/2027	2,341,132	371,910	293,362	408,659	16
3/31/2026	2,090,721	309,297	394,777	478,834	16
9/30/2025	1,978,882	279,895	-68,785	102,085	N/A
6/30/2025	1,924,678	295,873	-64,677	127,317	N/A
3/31/2025	1,886,256	295,756	-134,030	53,842	N/A
12/31/2024	1,795,986	245,770	-162,487	11,692	N/A
9/30/2024	1,758,071	250,400	417,387	587,088	N/A
6/30/2024	1,687,028	229,101	407,158	535,454	N/A
3/31/2024	1,601,688	200,731	476,467	599,258	N/A
12/31/2023	1,503,471	186,052	509,483	601,669	N/A
9/30/2023	1,397,025	147,885	-79,581	4,025	N/A
6/30/2023	1,348,996	147,350	15,149	89,040	N/A
3/31/2023	1,278,478	109,188	47,148	114,514	N/A
12/31/2022	1,182,201	59,354	52,831	120,225	N/A
9/30/2022	1,122,724	62,816	85,820	153,864	N/A
6/30/2022	1,061,140	50,603	74,484	148,554	N/A
3/31/2022	1,044,892	66,972	62,544	139,226	N/A
12/31/2021	1,034,692	94,470	91,294	161,092	N/A
9/30/2021	1,012,313	86,756	52,721	111,874	N/A
6/30/2021	989,638	79,321	58,547	106,238	N/A
3/31/2021	962,516	75,958	128,114	192,207	N/A
12/31/2020	963,552	70,599	123,806	188,054	N/A
9/30/2020	982,388	116,315	132,076	206,119	N/A
6/30/2020	969,501	117,584	96,878	174,904	N/A
3/31/2020	981,793	129,074	144,036	196,601	N/A
12/31/2019	983,669	148,891	137,641	212,138	N/A
9/30/2019	962,440	113,821	120,648	187,666	N/A
6/30/2019	953,219	112,805	N/A	181,424	N/A
3/31/2019	929,717	93,409	N/A	92,033	N/A
12/31/2018	922,228	66,479	N/A	85,284	N/A
9/30/2018	937,648	70,018	N/A	97,072	N/A
6/30/2018	946,829	55,081	N/A	96,957	N/A
3/31/2018	960,195	60,282	N/A	108,439	N/A
12/31/2017	961,766	37,887	N/A	99,826	N/A
9/30/2017	966,509	38,758	N/A	83,608	N/A
6/30/2017	953,255	52,017	N/A	102,946	N/A
3/31/2017	955,124	53,466	N/A	136,234	N/A
12/31/2016	962,296	59,736	N/A	161,540	N/A
9/30/2016	965,681	60,572	N/A	184,039	N/A
6/30/2016	989,001	77,951	N/A	181,513	N/A
3/31/2016	986,446	82,282	N/A	174,281	N/A
12/31/2015	839,759	55,256	N/A	139,346	N/A
9/30/2015	872,744	67,132	N/A	146,907	N/A
6/30/2015	903,340	61,708	N/A	151,239	N/A
3/31/2015	919,372	46,762	N/A	142,776	N/A
12/31/2014	1,149,342	88,276	N/A	N/A	N/A

애널리스트 향후 성장 전망

수입 대 저축률: 4568 의 연간 예상 수익 증가율(14.9%)이 saving rate(0.6%)보다 높습니다.

수익 vs 시장: 4568 의 연간 수익(14.9%)이 JP 시장(8.3%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: 4568 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 4568 의 수익(연간 10%)이 JP 시장(연간 4.5%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: 4568 의 수익(연간 10%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: 4568의 자본 수익률은 3년 후 20.4%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/04 10:39
종가	2025/12/04 00:00
수익	2025/09/30
연간 수익	2025/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Daiichi Sankyo Company, Limited는 26명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Atsushi Seki	Barclays
Koichi Mamegano	BofA Global Research
Hidemaru Yamaguchi	Citigroup Inc

Daiichi Sankyo Company 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year

Earnings Beat: Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Daiichi Sankyo Company, Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Daiichi Sankyo Company, Limited Just Recorded A 8.3% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen

Daiichi Sankyo Company, Limited to Report Q3, 2026 Results on Jan 30, 2026

Daiichi Sankyo Announces Dosed in First-In-Human Phase 1 Trial Evaluating Ds3610 in Patients with Advanced Solid Tumors

Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited Announces DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Present Initial Results For DATROWAY Plus Rilvegostomig Combination Therapy in Urothelial Cancer

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's

Daiichi Sankyo Company, Limited to Report Q2, 2026 Results on Oct 31, 2025

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Daiichi Sankyo Company (TSE:4568) Has Announced That It Will Be Increasing Its Dividend To ¥39.00

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across Adc Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer At Wclc

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

Earnings Beat: Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company (TSE:4568) Is Increasing Its Dividend To ¥39.00

Enhertu Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with Her2 Positive Metastatic Breast Cancer

Turalio Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of Enliven Phase 3 Trial

Daiichi Sankyo Company (TSE:4568) Is Increasing Its Dividend To ¥39.00

Less than half of directors are independent

Final dividend of JP¥39.00 announced

New minor risk - Share price stability

We Think That There Are Issues Underlying Daiichi Sankyo Company's (TSE:4568) Earnings

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Datroway Approves in Us for EGFRm Lung Cancer

Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Daiichi Sankyo Company, Limited to Report Q1, 2026 Results on Jul 31, 2025

DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw

IHH Healthcare Berhad Provides Update on Material Litigation by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

Daiichi Sankyo, Inc. Announces Positive Topline Results from the Destiny-Breast11 Phase 3 Trial

Daiichi Sankyo Company, Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 23, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

New minor risk - Dividend sustainability

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Is Daiichi Sankyo Company (TSE:4568) Using Too Much Debt?

Daiichi Sankyo and AstraZeneca's ENHERTU Approves in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Upcoming dividend of JP¥30.00 per share

Daiichi Sankyo Company, Limited to Report Fiscal Year 2025 Results on Apr 25, 2025

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 17,000,000 shares, representing 0.91% for ¥50,000 million.

Daiichi Sankyo and AstraZeneca's Enhertu Recommends for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark

New minor risk - Share price stability

Daiichi Sankyo Company, Limited Provides Updated on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd

Daiichi Sankyo Company, Limited Just Recorded A 8.3% EPS Beat: Here's What Analysts Are Forecasting Next

New major risk - Earnings quality

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025

Daiichi Sankyo's Datopotamab Deruxtecan is Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC and Daiichi Sankyo’ ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Approves in the US for the Treatment of Adult Patients with Unresectable or Metastatic Hormone Receptor (HR)-Positive, HER2-Low (IHC 1+ or IHC 2+/ISH-) or Her2-Ultralow (IHC 0 with Membrane Staining) Breast Cancer

Daiichi Sankyo Company, Limited's (TSE:4568) Intrinsic Value Is Potentially 93% Above Its Share Price

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca and Daiichi Sankyo Voluntarily Withdrawn the Marketing Authorisation Application in the EU for datopotamab deruxtecan (Dato-DXd)

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

First half dividend of JP¥30.00 announced

Quantum-Wild Phase 3 Trial of VANFLYTA Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML